Trade Name (Agent): Elzonris (tagraxofusp)
Sponsor: Stemline Therapeutics, Inc.
Date of BT Designation Disclosure: 6/15/2018
Approval Date: 12/21/2018
Indication: Adults and children aged 2 years and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Category: Cancer